A pleasant taste for your patients1
BUNAVAIL was designed with a likable, mild citrus taste to make it easier for your patients to administer their medicine as directed.
91.3% of patients switched from Suboxone® tablets or films to BUNAVAIL reported the taste of BUNAVAIL as very pleasant, pleasant, or neutral*
Low incidence of constipation is meaningful for your patients2
Part of fighting opioid dependence is patients getting back to the feeling of normalcy they experienced before the onset of addiction. In a survey of 606 patients conducted by the National Alliance of Advocates for Buprenorphine Treatment (NAABT):
74% reported constipation as a side effect of treatment
18% reported constipation as their “greatest frustration” with buprenorphine treatment
Decrease in patient-reported constipation1
Based on data from a self-administered symptom checklist for patients (n=186) after
12 weeks of treatment with BUNAVAIL, who had previously discontinued treatment with Suboxone tablets or films.
2.8% (7/249) of patients reported treatment-emergent constipation
Speak and swallow normally during administration3
- Absorption of buprenorphine is not affected by speaking or swallowing during administration
- Patients should avoid manipulating film with their tongue or finger(s) and avoid drinking or eating food until the film dissolves
- BUNAVAIL buccal film should not be chewed or swallowed as this may result in lower peak concentrations and lower bioavailability
Study Design: A 12-week, open-label, multicenter study assessed the safety and tolerability of BUNAVAIL buccal film for the maintenance treatment of opioid dependence in 249 subjects stabilized on 8/2 mg/day to 32/8 mg/day Suboxone tablet or film for at least 30 days.
- Sullivan JG, Webster L. Novel buccal film formulation of buprenorphine-naloxone for the maintenance treatment of opioid dependence: a 12-week conversion study. J Clin Ther. 2015;37(5):1064-1075.
- Soper RG, Bailey GL, Lepak T, Miller MM, Ziebro M. A survey of opioid-dependent patients treated with buprenorphine—self-reported side effects. Poster presented at: 26th Annual Meeting and Scientific Symposium of the American Academy of Addiction Psychiatry; December 3-6, 2015; Huntington Beach, CA.
- Vasisht N, Stark J, Bai SA, Finn A. Buprenorphine/naloxone buccal film has a relative buprenorphine bioavailability approximately twice that of buprenorphine/naloxone sublingual tablet. Poster presented at: 45th Annual American Society of Addiction Medicine (ASAM); April 10-13, 2014; Orlando, FL.